Rhythm Pharmaceuticals, INC Form 4 insider transactions

Chief Technical Officer Joseph Shulman of Rhythm Pharmaceuticals reports the acquisition and disposal of common stock and restricted stock units.

Jennifer Kayden Lee, EVP, Head of North America at Rhythm Pharmaceuticals, reports the exercise of stock options and sale of common stock, including transactions pursuant to a 10b5-1 trading plan.

Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, sold shares of common stock to cover withholding taxes related to vesting restricted stock units.

Hunter C. Smith, CFO of Rhythm Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units to cover withholding taxes.

EVP Jennifer Kayden Lee of Rhythm Pharmaceuticals sold shares of common stock on February 5, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Hunter C. Smith, CFO of Rhythm Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Rhythm Pharmaceuticals' CEO, David Meeker, reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Jennifer Kayden Lee, EVP at Rhythm Pharmaceuticals, sold shares to cover withholding taxes related to vesting restricted stock units.

Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, sold 902 shares of common stock on February 4, 2025, to cover withholding taxes related to vesting restricted stock units.

Jennifer Kayden Lee, EVP at Rhythm Pharmaceuticals, sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, exercised stock options and sold shares on November 11, 2024, according to a recent SEC filing.

Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, amended a previous SEC filing to correct the number of stock options exercised on February 9, 2024.

Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, executed stock options and sold shares of common stock on November 6th and 7th, 2024, according to a recent SEC filing.

Director Jennifer Good exercised stock options and sold shares of Rhythm Pharmaceuticals on September 17, 2024, according to a Form 4 filing.

Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, executed stock options and sold shares on September 9, 2024, according to a Form 4 filing with the SEC.

Director Lynn A. Tetrault reports exercising stock options and selling shares of Rhythm Pharmaceuticals common stock on September 9th and 10th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Jennifer Good exercised stock options and sold shares of Rhythm Pharmaceuticals common stock on September 9, 2024, according to a Form 4 filing with the SEC.

Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Director Lynn A. Tetrault exercised stock options and sold shares of Rhythm Pharmaceuticals, Inc. on August 26, 2024, according to a Form 4 filing with the SEC.

Director Jennifer L. Good exercised stock options and sold shares of Rhythm Pharmaceuticals (RYTM) on August 26, 2024, according to a Form 4 filing with the SEC.

Director Lynn A. Tetrault exercised stock options and sold shares of Rhythm Pharmaceuticals, Inc. on August 12, 2024, according to a Form 4 filing with the SEC.

Pamela Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, exercised stock options and sold shares on August 9, 2024, according to a Form 4 filing with the SEC.

Pamela Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Chief Technical Officer Joseph Shulman of Rhythm Pharmaceuticals exercised stock options and sold shares on July 16, 2024.

Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, exercised stock options and sold shares on July 12, 2024, according to a Form 4 filing with the SEC.

Alastair Garfield, Chief Scientific Officer of Rhythm Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Director Stuart A. Arbuckle reports exercising stock options for 3,000 shares of Rhythm Pharmaceuticals common stock on June 21, 2024.

Director David W.J. McGirr exercised options to acquire 3,000 shares of Rhythm Pharmaceuticals common stock on June 21, 2024.

Director Lynn A. Tetrault reports the vesting and conversion of restricted stock units into Rhythm Pharmaceuticals common stock.